No matches

Type 2 Inflammation

ATS 2024 | Type 2 Inflammation in the Pathophysiology of Asthma and COPD: What Is It and How Does It Impact Patients?

Join experts Mario Castro, Nicola Hanania, and Stephanie Christenson for an educational symposium on the real-world impact of underlying type 2 inflammation on the patient burden of asthma and COPD.

MD, MPH

Mario Castro +2 more

See post-event materials

Past event

20May2024

Location

Manchester Grand Hyatt San Diego - Seaport Ballroom FGH

San Diego, CA United States

Learning objectives

Understand the shared and unique disease burden in COPD with type 2 inflammation and moderate-to-severe asthma
Identify the role of type 2 inflammation in the pathophysiology of moderate-to-severe asthma and COPD with type 2 inflammation
Differentiate between the clinical manifestations of type 2 inflammation in moderate-to-severe asthma and COPD with type 2 inflammation using real-world patient cases

Description

Join the ADVENT program at the ATS 2024 conference in San Diego for an educational symposium on the shared and unique pathophysiological features of type 2 inflammation-driven asthma and COPD and their real-world impact on patients.

Don't miss your opportunity to hear directly from global experts in pulmonology during the live audience Q&A following the presentations.

Agenda

Welcome and Introductions

Mario Castro (Chair)

Patient Burden and Airway Remodeling in Asthma

Nicola Hanania

COPD with Type 2 Inflammation: Patient Burden and Fixed Airway Obstruction

Stephanie Christenson

Overview of Type 2 Inflammation in Airway

Mario Castro

Panel Discussion: Airway Inflammation - Burden and Outcome

All Faculty

Q&A

All Faculty

Location

Manchester Grand Hyatt San Diego - Seaport Ballroom FGH

San Diego, CA United States

Speakers

Pulmonology

MD, MPH

Mario Castro

Chief, Pulmonary, Critical Care and Sleep Medicine; Vice Chair for Clinical and Translational Research, University of Kansas School of Medicine

Pulmonology

MD, MS, FCCP, FACP, FRCP, FERS

Nicola A. Hanania

Professor of Medicine, Section of Pulmonary and Critical Care Medicine; Director, Airways Clinical Research Center, Baylor College of Medicine; Chief, Section of Pulmonary, Critical Care and Sleep Medicine, Ben Taub Hospital

Pulmonology

MD, MAS

Stephanie Christenson

Associate Professor at the University of California, San Francisco in the Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine

Related resources

Worsening Disease Results in a Vicious Cycle of COPD

Pulmonology

5 min

interactivity

Worsening Disease Results in a Vicious Cycle of COPD

Pathways to Disease: Inflammation in COPD

Pulmonology

5 min

interactivity

Pathways to Disease: Inflammation in COPD

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region

Type 2 Inflammation

ATS 2024 | Type 2 Inflammation in the Pathophysiology of Asthma and COPD: What Is It and How Does It Impact Patients?

Join experts Mario Castro, Nicola Hanania, and Stephanie Christenson for an educational symposium on the real-world impact of underlying type 2 inflammation on the patient burden of asthma and COPD.

MD, MPH

Mario Castro +2 more

See post-event materials

Past event

20May2024

Location

Manchester Grand Hyatt San Diego - Seaport Ballroom FGH

San Diego, CA United States

Learning objectives

Understand the shared and unique disease burden in COPD with type 2 inflammation and moderate-to-severe asthma
Identify the role of type 2 inflammation in the pathophysiology of moderate-to-severe asthma and COPD with type 2 inflammation
Differentiate between the clinical manifestations of type 2 inflammation in moderate-to-severe asthma and COPD with type 2 inflammation using real-world patient cases